

Post-Traumatic Stress Disorder (PTSD) Global Clinical Trials Review H2 2016

Post-Traumatic Stress Disorder (PTSD) Global Clinical Trials Review, H2, 2016

PUNE, INDIA, November 16, 2016 /EINPresswire.com/ -- This report provides top line data relating to the clinical trials on Post-Traumatic Stress Disorder (PTSD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on



number of ongoing trials). Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/735119-post-traumatic-stress-disorder-ptsd-global-clinical-trials-review-h2-2016

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Post-Traumatic Stress Disorder (PTSD) to Central

Nervous System Clinical Trials 15

Clinical Trials by Phase in G7 Countries 17

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Post-Traumatic Stress Disorder (PTSD) to Central

Nervous System Clinical Trials 19

Clinical Trials by Phase in E7 Countries 21

Clinical Trials in E7 Countries by Trial Status 22

Clinical Trials by Phase 23

In Progress Trials by Phase 24

Clinical Trials by Trial Status 25

Clinical Trials by End Point Status 26

Subjects Recruited Over a Period of Time 27

Clinical Trials by Sponsor Type 28

Prominent Sponsors 29

Top Companies Participating in Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials 30

Prominent Drugs 32

Latest Clinical Trials News on Post-Traumatic Stress Disorder (PTSD) 33

Sep 16, 2016: Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP 33

Aug 29, 2016: Tonix Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for

TNX-102 SL in Post-Traumatic Stress Disorder 33

Clinical Trial Profile Snapshots 35

Appendix 219

Abbreviations 219

Access Report @ https://www.wiseguyreports.com/reports/735119-post-traumatic-stress-disorder-ptsd-global-clinical-trials-review-h2-2016

Get in touch:

LinkedIn: <u>www.linkedin.com/company/4828928</u>
Twitter: <u>https://twitter.com/WiseGuyReports</u>

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.